Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in Series A financing.
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Podcast
Learn what's fueling San Diego's biotech investment and partnership opportunities
